Cooperative Agreement U01CA288665
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$406K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Cooperative Agreement
Place of Performance
Massachusetts, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $356,850 Cooperative Agreement (CFDA 93.395 - Cancer Treatment Research) to Oregon Health & Science University (OHSU) to characterize the pre-analytical steps involved in blood and bone marrow biopsy sample handling and storage/retrieval for functional assay reporting. The project aims to establish pre-analytical sample processing guidelines to enable maximal reproducibility for functional testing outcomes, including high throughput-drug...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $872,555 to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA over a five-year period from September 1, 2024 to August 31, 2029. The award aims to catalyze long-read cancer genome sequencing efforts through the development of informatic methods for the discovery and characterization of somatic genetic alterations in cancer genomes. Key objectives include improving...
This federal Cooperative Agreement award for $811,500.00 from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports research to bridge the gap between bioinformatics and mathematical modeling for patient-specific tumor modeling. The project aims to merge bioinformatics software for analyzing single-cell and spatial multi-omics data with an agent-based modeling framework to simulate cell interactions in virtual tumor environments. Key objectives include refining a cell...
The National Cancer Institute (NCI) awarded a $647,458 Cooperative Agreement under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Massachusetts Institute of Technology (MIT) to develop a novel platform for real-time functional assessment of Acute Myeloid Leukemia (AML) minimal residual disease (MRD) therapeutic vulnerabilities. The project aims to integrate MIT's high-precision biophysical measurements, DeepCell's label-free brightfield imaging and AI-powered sorting,...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $427,095 to Northeastern University to develop a novel microfluidic droplet-based platform (MDP) technology. The MDP will generate and analyze a 3D biomimetic multicellular immunogenic tumor model to: Establish multiple levels of hypoxia within the same tumor-chip for parallel processing. Investigate spatiotemporal interaction between the...
This $440,171 Cooperative Agreement was awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Fred Hutchinson Cancer Center in Seattle, Washington to systematically investigate and mitigate the impact of pre-analytical variables on the accuracy and reliability of mass spectrometry-based quantification of immunomodulatory proteins in cerebrospinal fluid (CSF) from pediatric brain tumor patients participating in clinical trials. The key objectives are to: (1)...
This federal Project Grant award of $470,567.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Beth Israel Deaconess Medical Center, Inc. (BIDMC) aims to identify molecular features that influence response or resistance to PARP-inhibitor treatment in metastatic breast cancer patients without germline BRCA1/2 mutations. The award will fund analysis of pre-treatment tumor DNA and pre- and post-treatment circulating tumor DNA samples from 108 patients enrolled in...
The National Cancer Institute (NCI) awarded a $831,565 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to the University of Massachusetts Medical School (UMass Medical) to develop an Integrative Analysis and Visualization Platform for Cancer Regulatory Genomics. The project aims to create a Regulatory-Element-Target-Gene Atlas that will enable researchers to explore connections between regulatory elements and genes associated with cancer. It will also perform...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $590,960.00 in funding to the Beckman Research Institute of the City of Hope to conduct research aimed at improving the understanding and treatment of acute myeloid leukemia (AML). The key objectives of the project are to: 1) Quantify the dynamics of leukemia potential driven by different oncogenic signals in murine models, 2) Evaluate the effects of treatment on leukemia...
This federal Cooperative Agreement award in the amount of $485,790 was issued on May 1, 2025 by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program. The award is being provided to the University of Massachusetts Medical School (UMass Medical) in Worcester, MA to study the efficacy of tyrosine kinase inhibitors, such as imatinib, in restoring DNA damage response and preventing the onset of hematologic malignancies in patients with familial...